Using the Earnings Power Value framework with a WACC of 7.3% and normalized earnings of $8.0B, Thermo Fisher Scientific Inc. has a fair value of $209.35 per share. The EPV range is $159.72 – $284.59 based on WACC sensitivity (5.8% – 8.8%).
| Low | Selected | High | |
|---|---|---|---|
| Normalized Earnings | 8,039 | 8,039 | 8,039 |
| (/) WACC | 8.8% | 7.3% | 5.8% |
| Enterprise Value | 91,214 | 109,924 | 138,290 |
| (-) Net debt | 30,998 | 30,998 | 30,998 |
| Equity Value | 60,216 | 78,926 | 107,292 |
| (/) Outstanding shares | 377 | 377 | 377 |
| Fair Price | $159.72 | $209.35 | $284.59 |
Earnings Power Value (EPV) estimates what a company is worth based on its current normalized earnings, assuming zero growth. It values the business as a perpetuity: Normalized Earnings / WACC. This gives a conservative floor value — the company's worth if it never grows but maintains its current profitability.
The model normalizes earnings by: (1) using sustainable gross margins (5-year average) applied to current revenue, (2) deducting maintenance-level operating expenses (average R&D + SG&A as % of revenue), (3) applying the average effective tax rate, and (4) subtracting the average excess of CapEx over D&A (net reinvestment needed to maintain current capacity).
EPV is most useful as a comparison anchor: if the market price is below EPV, the stock may be undervalued even without any growth. If market price exceeds EPV, the premium reflects growth expectations — which may or may not materialize.